BSEBeryl Drugs LtdLowNeutral
Announced Wed, 25 Mar · 21:18 IST

DISCLOSURE UNDER REGULATION 29(2) OF SEBI(SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOEVRS)REGULATIONS, 2011

Promoter Stake BuyOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-5.0%1-day move
₹20.30
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-5.0-6.5-7.1-7.1+11.2+28.0+16.0+8.4-2.2+8.4
Up moveDown movePending
AI summary

Mr. Sudhir Sethi, a main promoter of Beryl Drugs Ltd, acquired 7,500 equity shares (0.14% of total share capital) through open market transactions on 24 March 2026. Before this acquisition, the promoter held 4,86,483 shares (9.58% stake); after the acquisition, his holding stands at 4,93,983 shares (9.72% stake). The total equity share capital of the company remains unchanged at 50,71,700 shares. Other promoters listed in the disclosure include Sanjay Sethi, Sangita Sethi, and Soniya Sethi. The acquisition was disclosed under Regulation 29(2) of SEBI Takeover Regulations.

Likely market impact

This is a small, incremental promoter purchase through the open market, signaling mild promoter confidence in the company. The acquisition increases the promoter's stake marginally from 9.58% to 9.72%, which is generally viewed positively by retail investors as it indicates insider buying, though the size is modest.